公开(公告)号：US20190382359A1

公开(公告)日：2019-12-19

申请号：US16547037

申请日：2019-08-21

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D493/10 ,  C07D405/12 ,  C07D413/14 ,  C07D405/14 ,  C07F9/6561 ,  C07D515/10 ,  C07D471/08 ,  C07D211/48 ,  C07D487/04 ,  C07D471/10 ,  C07D401/12 ,  C07D491/107 ,  C07D498/10 ,  C07D403/04 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20180208608A1

公开(公告)日：2018-07-26

申请号：US15876698

申请日：2018-01-22

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  CHRISTOPHER JOHN HELAL ,  STEVEN VICTOR O'NEIL ,  PATRICK ROBERT VERHOEST

IPC: C07D513/10 ,  C07D221/20 ,  A61P35/00 ,  A61P3/00 ,  A61P9/00 ,  A61P25/00

Abstract: The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20180200253A1

公开(公告)日：2018-07-19

申请号：US15923285

申请日：2018-03-16

Applicant: PFIZER INC.

Inventor： JOTHAM WADSWORTH COE ,  JOHN ARTHUR ALLEN ,  JENNIFER ELIZABETH DAVOREN ,  AMY BETH DOUNAY ,  IVAN VIKTOROVICH EFREMOV ,  DAVID LAWRENCE FIRMAN GRAY ,  EDWARD RAYMOND GUILMETTE ,  ANTHONY RICHARD HARRIS ,  CHRISTOPHER JOHN HELAL ,  JACLYN LOUISE HENDERSON ,  SCOT RICHARD MENTE ,  DEANE MILFORD NASON ,  STEVEN VICTOR O'NEIL ,  CHAKRAPANI SUBRAMANYAM ,  WENJIAN XU

IPC: A61K31/53 ,  A61K31/519 ,  A61K31/506 ,  A61K31/5025 ,  A61K31/501 ,  A61K31/4355 ,  A61K31/497 ,  A61K31/437 ,  A61K31/4365 ,  A61K31/4985

CPC classification number: A61K31/53 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61P25/00 ,  A61P25/06 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  C07D519/04

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds and the uses of such compounds for the treatment of D1-mediated (or D1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, Parkinson's disease, Mild cognitive impairment (MCI), Alzheimer's disease, lupus, Huntington's disease, Parkinson's, dyskinesia, ADHD, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (MDD), drug dependence, Tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension.

公开(公告)号：US20180065943A1

公开(公告)日：2018-03-08

申请号：US15808242

申请日：2017-11-09

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D405/14 ,  C07D413/14 ,  C07D515/10 ,  C07D471/08 ,  C07D211/48 ,  C07D487/04 ,  C07D471/10 ,  C07D401/12 ,  C07D491/107 ,  C07D498/10 ,  C07D403/04 ,  C07D401/04 ,  C07D401/14 ,  C07D493/10 ,  C07D405/12 ,  C07F9/6561

CPC classification number: C07D295/14 ,  C07D211/48 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D493/10 ,  C07D498/10 ,  C07D515/10 ,  C07F9/6561

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20190276472A1

公开(公告)日：2019-09-12

申请号：US16420544

申请日：2019-05-23

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  CHRISTOPHER JOHN HELAL ,  STEVEN VICTOR O'NEIL ,  PATRICK ROBERT VERHOEST

IPC: C07D513/10 ,  C07D295/185 ,  C07D491/10 ,  C07D221/20 ,  C07D401/08 ,  C07D401/12

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20180208607A1

公开(公告)日：2018-07-26

申请号：US15874987

申请日：2018-01-19

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  CHRISTOPHER JOHN HELAL ,  STEVEN VICTOR O'NEIL ,  PATRICK ROBERT VERHOEST

IPC: C07D513/10 ,  C07D221/20

CPC classification number: C07D513/10 ,  C07D221/20 ,  C07D295/185 ,  C07D401/08 ,  C07D401/12 ,  C07D491/10

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20170029390A1

公开(公告)日：2017-02-02

申请号：US15221658

申请日：2016-07-28

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D401/04 ,  C07D403/04 ,  C07D498/10 ,  C07D491/107 ,  C07D405/14 ,  C07D471/10 ,  C07D487/04 ,  C07D211/48 ,  C07D471/08 ,  C07D515/10 ,  C07F9/6561 ,  C07D401/14 ,  C07D401/12

CPC classification number: C07D295/14 ,  C07D211/48 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D493/10 ,  C07D498/10 ,  C07D515/10 ,  C07F9/6561

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract translation: 和其药学上可接受的盐; 制备过程; 中间体用于制备; 含有这些化合物或盐的组合物及其用于治疗MAGL介导的疾病和病症的用途，包括例如疼痛，炎性疾病，创伤性脑损伤，抑郁症，焦虑症，阿尔茨海默病，代谢紊乱，中风或癌症。